Pacira BioSciences (PCRX) Return on Capital Employed (2011 - 2026)
Pacira BioSciences' (PCRX) quarterly Return on Capital Employed came in at 2.14% in Q1 2026, up 888.0% year-on-year from 0.22% in Q1 2025, and up 29.24% quarter-over-quarter from 1.65% in Q4 2025.
Pacira BioSciences (PCRX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Pacira BioSciences' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 2.14% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 888.0% year-over-year to 2.14% in Q1 2026; TTM through Mar 2026 was 2.14%, a 888.0% increase from a year earlier, with the FY2025 full-year figure at 1.49%, up 734.0% from the prior year.
- Return on Capital Employed improved to 2.14% in Q1 2026 per PCRX's latest filing, from 1.65% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 7.0% in Q1 2024 and bottomed at 8.35% in Q2 2025.
- The 5-year median for Return on Capital Employed is 3.17% (2025), against an average of 1.63%.
- Across the five-year window, Return on Capital Employed sank 1442 bps in 2025 and jumped 888 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 3.85% in 2022, then soared by 56 bps to 6.02% in 2023, then slumped by 199 bps to 5.98% in 2024, then jumped by 128 bps to 1.65% in 2025, then rose by 29 bps to 2.14% in 2026.
- Per Business Quant, the three latest PCRX Return on Capital Employed figures stand at 2.14% (Q1 2026), 1.65% (Q4 2025), and 3.17% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Pacira BioSciences | 1.05 Bn | 846.97 Mn | 140.96 Mn | 2.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.14% |
| Dec 31, 2025 | 1.65% |
| Sep 30, 2025 | 3.17% |
| Jun 30, 2025 | -8.35% |
| Mar 31, 2025 | -6.74% |
| Dec 31, 2024 | -5.98% |
| Sep 30, 2024 | -5.08% |
| Jun 30, 2024 | 6.07% |
| Mar 31, 2024 | 7.00% |
| Dec 31, 2023 | 6.02% |
| Sep 30, 2023 | 3.09% |
| Jun 30, 2023 | 3.38% |
| Mar 31, 2023 | 2.63% |
| Dec 31, 2022 | 3.85% |
| Sep 30, 2022 | 4.63% |
| Jun 30, 2022 | 5.02% |
| Mar 31, 2022 | 5.24% |
| Dec 31, 2021 | 7.53% |
| Sep 30, 2021 | 9.37% |
| Jun 30, 2021 | 8.41% |